UNC3230
Based on 10 publication(s) in Google Scholar
UNC3230 is a potent, selective and ATP-competitive PIP5K1C inhibitor with an IC50 of ~41 nM. UNC3230 also inhibits PIP4K2C and does not inhibit any of the other lipid kinases that regulate phosphoinositide levels. UNC3230 has antinociceptive and anticancer effects.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.39%
- CAS 番号: 1031602-63-7
- 分子式: C17H20N4O2S
- 分子量:344.43
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Targeted Diversity Library
HY-L099
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
MedChemExpress（MCE）の使用を引用している文献 UNC3230
More- J Extracell Vesicles. 2023 Apr;12(4):e12319. [Abstract]
- Exp Mol Med. 2024 Aug;56(8):1736-1749. [Abstract]
- Sci Immunol. 2025 Jun 27;10(108):eadn1630. [Abstract]
- Breast Cancer Res. 2023 Oct 6;25(1):119. [Abstract]
- Cells. 2024 Jan 31;13(3):270. [Abstract]
- Int Immunopharmacol. 2026 Aug 1:182:116808. [Abstract]
- Int J Mol Sci. 2023 Sep 30;24(19):14786. [Abstract]
- bioRxiv. 2026 Mar 5.
- bioRxiv. 2026 Jan 2.
- bioRxiv. 2023 Feb 23.
Customer Validation & Images
-
WB
-
IF
-
Cell Imaging/Staining
生物活性
IC50: ~41 nM (Phosphatidylinositol 4-phosphate 5 kinase type 1C (PIP5K1C))[1]
Membrane PIP2 levels are significantly reduced by ~45% in dorsal root ganglia (DRG) neurons treated with 100 nM UNC3230 (~2-fold above the IC50) relative to vehicle controls. UNC3230 significantly reduces lysophosphatidic acid (LPA)-evoked calcium signaling in cultured DRG neurons relative to vehicle[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
UNC3230 (2 nmol; intrathecal injection) is administered then one hour later co-injected 1 nmol LPA with UNC3230 (2 nmol, intrathecal injection). UNC3230 significantly blunts thermal hyperalgesia and mechanical allodynia compared to vehicle[1].
UNC3230 (2 nmol; intrathecal injection) significantly blunts thermal hyperalgesia and mechanical allodynia in the complete Freund’s adjuvant (CFA)-inflamed hindpaw (relative to vehicle control) but does not affect thermal or mechanical sensitivity in the control (non-inflamed) hindpaw over a multiday time course[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 1031602-63-7
-
性状 Solid
-
分子量 344.43
-
分子式 C17H20N4O2S
-
Color Off-white to light yellow
-
SMILES
O=C(C1=C(NC(C2CCCCC2)=O)SC(NC3=CC=CC=C3)=N1)N
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (10)
-
Journal Impact Factor
-
Most Recent
-
J Extracell Vesicles
Exosomal lipid PI4P regulates small extracellular vesicle secretion by modulating intraluminal vesicle formation. [Abstract]2023 Apr;12(4):e12319. PMID: 37021404 -
Exp Mol Med
2024 Aug;56(8):1736-1749. PMID: 39085352
UNC3230 purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2024 Aug;56(8):1736-1749. [Abstract]
Western blot analysis of p62, LC3B-I, LC3B-II and GAPDH in the presence of UNC3230 (0.5 μM), apilimod and UNI418.
UNC3230 purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2024 Aug;56(8):1736-1749. [Abstract]
Immunofluorescence staining with LC3B (green) and p62 (red) antibodies upon treatment with UNC3230 (0.5 μM).
-
Sci Immunol
Radiotherapy enhances anticancer CD8 T cell responses by cGAMP transfer through LRRC8A/C volume-regulated anion channels. [Abstract]2025 Jun 27;10(108):eadn1630. PMID: 40577443 -
Breast Cancer Res
MiR-4649-5p acts as a tumor-suppressive microRNA in triple negative breast cancer by direct interaction with PIP5K1C, thereby potentiating growth-inhibitory effects of the AKT inhibitor capivasertib. [Abstract]2023 Oct 6;25(1):119. PMID: 37803350 -
Cells
Evidence for Involvement of ADP-Ribosylation Factor 6 in Intracellular Trafficking and Release of Murine Leukemia Virus Gag. [Abstract]2024 Jan 31;13(3):270. PMID: 38334661 -
Int Immunopharmacol
IITZ01 attenuates fructose aggravated ulcerative colitis via prevention of macrophage activation and decrease in cytokine release via inhibition of PIP5 kinase. [Abstract]2026 Aug 1:182:116808. PMID: 42140165 -
Int J Mol Sci
PIP5Kγ Mediates PI(4,5)P2/Merlin/LATS1 Signaling Activation and Interplays with Hsc70 in Hippo-YAP Pathway Regulation. [Abstract]2023 Sep 30;24(19):14786. PMID: 37834234
UNC3230 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Sep 30;24(19):14786. [Abstract]
Colony formation assay was performed using HeLa cells treated with UNC3230 (100 nM) and/or the YAP inhibitor verteporfin (VP, 1 μM).
-
-
-
溶剤 & 溶解度
DMSO : 125 mg/mL (362.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Wright BD, et al. The lipid kinase PIP5K1C regulates pain signaling and sensitization. Neuron. 2014 May 21;82(4):836-47. [Content Brief]
[2]. Peng W, et al. Type Iγ phosphatidylinositol phosphate kinase promotes tumor growth by facilitating Warburg effect in colorectal cancer. EBioMedicine. 2019 Jun;44:375-386. [Content Brief]
[3]. Wright BD, et al. Development of a High-Throughput Screening Assay to Identify Inhibitors of the Lipid Kinase PIP5K1C. J Biomol Screen. 2015 Jun;20(5):655-62. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9033 mL | 14.5167 mL | 29.0335 mL | 72.5837 mL |
| 5 mM | 0.5807 mL | 2.9033 mL | 5.8067 mL | 14.5167 mL | |
| 10 mM | 0.2903 mL | 1.4517 mL | 2.9033 mL | 7.2584 mL | |
| 15 mM | 0.1936 mL | 0.9678 mL | 1.9356 mL | 4.8389 mL | |
| 20 mM | 0.1452 mL | 0.7258 mL | 1.4517 mL | 3.6292 mL | |
| 25 mM | 0.1161 mL | 0.5807 mL | 1.1613 mL | 2.9033 mL | |
| 30 mM | 0.0968 mL | 0.4839 mL | 0.9678 mL | 2.4195 mL | |
| 40 mM | 0.0726 mL | 0.3629 mL | 0.7258 mL | 1.8146 mL | |
| 50 mM | 0.0581 mL | 0.2903 mL | 0.5807 mL | 1.4517 mL | |
| 60 mM | 0.0484 mL | 0.2419 mL | 0.4839 mL | 1.2097 mL | |
| 80 mM | 0.0363 mL | 0.1815 mL | 0.3629 mL | 0.9073 mL | |
| 100 mM | 0.0290 mL | 0.1452 mL | 0.2903 mL | 0.7258 mL |
UNC3230 関連分類
HY-110150 関連分類
Powered by Bioz